CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $28.73M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 2.06: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.00BUSDvs all stocks (USD)
Revenue (TTM)
28.73MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.50xvs all stocks
52-Week Change
61.01%vs all stocks
Market Capitalization
1.00BUSDvs all stocks (USD)
Enterprise Value
421.02MUSDvs all stocks (USD)
Forward P/E
-6.28xvs Biotechnology peers
Price to Sales (TTM)
34.95xvs Biotechnology peers
Price to Book (MRQ)
2.06xvs Biotechnology peers
Enterprise to Revenue
14.66xvs Biotechnology peers
Enterprise to EBITDA
-2.42xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-547.84%vs Biotechnology peers
Return on Assets (TTM)
-21.63%vs Biotechnology peers
Return on Equity (TTM)
-42.66%vs Biotechnology peers
Revenue (TTM)
28.73MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3110USDUpdated Sep 27, 2026Quarterly Revenue Growth
-61.30%vs Biotechnology peers
Gross Profit (TTM)
-133.63MUSDvs all stocks (USD)
EBITDA (TTM)
-173.73MUSDvs all stocks (USD)
Net Income (TTM)
-161.12MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-61.33%vs Biotechnology peers
Operating Cash Flow (TTM)
-24.07MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-74.45MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
123.67MUSDFY2025 · Dec 31, 2025Operating Income
-54.21MUSDvs all stocks (USD)
Pre-tax Income
-39.72MUSDFY2025 · Dec 31, 2025Income Tax Expense
-1.10MUSDFY2025 · Dec 31, 2025Net Income
-38.63MUSDFY2025 · Dec 31, 2025EBIT
-54.21MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-47.40MUSDFY2025 · Dec 31, 2025Research & Development
141.50MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
36.38MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.94MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-38.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-29.05MUSDFY2025 · Dec 31, 2025Free Cash Flow
-33.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
134.84MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-38.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
8.36MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.86MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.43MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-13.71MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
7.49MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.70MUSDFY2025 · Dec 31, 2025Purchase of Investments
-376.68MUSDFY2025 · Dec 31, 2025Sale of Investments
279.54MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-101.83MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-357.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
23.89MUSDFY2025 · Dec 31, 2025Shares Outstanding
85.23MSharesUpdated Sep 27, 2026Float Shares
54.48MSharesUpdated Sep 27, 2026Shares Short
19.27MSharesUpdated Sep 27, 2026Short Ratio
17.13daysvs all stocks
Short % of Shares Outstanding
22.94%vs all stocks
% Held by Insiders
0.56%vs all stocks
% Held by Institutions
116.10%vs all stocks
Total Cash (MRQ)
621.10MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.28USDUpdated Sep 27, 2026Total Debt (MRQ)
37.99MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0780xvs Biotechnology peers
Current Ratio (MRQ)
10.58xvs Biotechnology peers
Book Value per Share (MRQ)
5.72USDUpdated Sep 27, 2026Total Assets
448.66MUSDvs all stocks (USD)
Total Current Assets
393.19MUSDFY2025 · Dec 31, 2025Total Liabilities
215.60MUSDFY2025 · Dec 31, 2025Total Non-current Assets
55.47MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
151.39MUSDFY2025 · Dec 31, 2025Total Current Liabilities
64.21MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
129.88MUSDFY2025 · Dec 31, 2025Other Short-term Investments
247.22MUSDFY2025 · Dec 31, 2025Accounts Payable
3.55MUSDFY2025 · Dec 31, 2025Short-term Debt
4.40MUSDFY2025 · Dec 31, 2025Deferred Revenue
29.57MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.58MUSDFY2025 · Dec 31, 2025Long-term Debt
34.79MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-477.21MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
233.06MUSDvs all stocks (USD)
52-Week Low
7.09USDUpdated Sep 27, 202652-Week High
25.77USDUpdated Sep 27, 202652-Week Change
61.01%vs all stocks
Beta
1.50xvs all stocks
50-Day MA
16.27USDUpdated Sep 27, 2026200-Day MA
18.36USDUpdated Sep 27, 2026Avg 10-Day Volume
1.30MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.14MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.75USDUpdated Sep 27, 2026Other Income / Expense
1.54MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 34.95Revenue Growth YoY: -0.61
Financial Health
Altman Z-Score 2.06: grey zoneSignificant
Altman Z-Score: 2.06
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $28.73M, lower than 95% of all stocks globallySignificant
Revenue (USD): 28,727,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Sunflower Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Janux Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vor Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Beijing Xiaocheng Technology Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated